New and Updated Antipsychotics Pathways
CPIC is currently evaluating evidence on antipsychotics and CYP2D6, CYP3A4 and CYP2C19 for the development of guidelines. To support this ClinPGx curators have expanded our set of antipsychotics pathways; updating and developing some of our in progress pathways and curating some new ones.
CPIC experts are closely evaluating the evidence on antipsychotics and the metabolizing enzymes CYP2D6, CYP3A4, and CYP2C19 as they work toward developing a new PGx guideline. To support this effort, ClinPGx scientists have expanded our antipsychotic pharmacokinetic (PK) pathway collection; updating several existing pathways and adding brand-new ones.
Explore them here:
Aripiprazole PK updated
Brexpiprazole PK updated
Cariprazine PK updated
Clozapine PK
Haloperidol PK
Iloperidone PK new
Olanzapine PK
Pimozide PK
Quetiapine PK updated
Risperidone and Paliperidone PK updated
Thioridazine PK new
Zuclopenthixol PK new
We’d love to hear your feedback! Tell us what you find most helpful, what may be missing, and what you’d like to see next at feedback@clinpgx.org
Do you use ClinPGx Pathways in your research, clinical work, or teaching? If so, would you be willing to answer a few questions or participate in a focus group about pathways? Please let us know at at feedback@clinpgx.org